Presently, over 40 companies worldwide have taken initiatives to develop drug therapies targeting myeloid cells

Given the potential of myeloid cells targeting therapies to treat multiple oncological and non-oncological disorders, such therapies have generated significant interest within the medical research community

London

Roots Analysis has announced the addition of “Myeloid Cell Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

The report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the myeloid cells targeting therapeutics market. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the report includes:

• A detailed assessment of the current market landscape of drug developers engaged in the development of myeloid cells targeting therapeutics.
• Elaborate profiles of key players engaged in the development of myeloid cells targeting therapeutics.
• A detailed analysis of completed and ongoing clinical trials of various myeloid cells targeting therapeutics.
• A detailed review of more than 10,000 peer-reviewed, scientific articles related to research on myeloid cells targeting therapeutics.
• An analysis of the partnerships that have been established in this domain since 2017, covering instances of research and development agreement, clinical trials agreement, merger / acquisition, product development and commercialization agreement, licensing agreement, asset acquisition and product development and manufacturing agreement.
• A detailed analysis of the various investments made since 2017, including grants, seed financing, venture capital financing, IPOs, secondary offering, other equity, post IPO equity and equity crowdfunding in the companies focused on the development of myeloid cells targeting therapeutics.
• An analysis of start-ups / small companies engaged in the development of myeloid cells targeting therapeutics.
• A case study on the companies developing macrophage-based therapeutics.
• A detailed market forecast, featuring analysis of the current and projected opportunity across key market segments (listed below)
  • Type of Molecule
    • Small Molecule
    • Biologics
  • Therapeutic Area
    • Oncological Disorders
    • Rare Disorders
  • Type of Therapy
    • Combination Therapy
    • Monotherapy
  • Route of Administration
    • Intravenous
    • Oral
  • Geography
    • North America
    • Europe
    • Asia Pacific

Key companies covered in the report

• ChemoCentryx
• Daiichi Sankyo
• Gilead Sciences
• AstraZeneca
• Enlivex
• GlaxoSmithKline
• Immune-Onc Therapeutics
• Infinity Pharmaceuticals
• Janssen
• Macrophage Pharma
• Pfizer
• Roche

For additional details, please visit

https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1. Squamous Non-Small Cell Lung Cancer Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com

Facebook – https://www.facebook.com/RootsAnalysis

LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter – https://twitter.com/RootsAnalysis

Medium – https://medium.com/@RootsAnalysis

Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/

Quora – https://rootsanalysisinsights.quora.com/